It's a shame that this trial had to stall the way it did when it could have provided valuable study data to compare with the BOM sub-study. That is comparing end Stage Renal with eGFR below <30 to below <60 if I'm understanding this correctly when the below <30 trial would have taken only one-year based on the trial update.